Should You Buy Dbv Technologies SA (DBVT) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
DBVT is **not a good buy right now** for a **beginner, long-term** investor with $50k–$100k who wants to enter immediately. While Wall Street turned strongly bullish after Phase 3 success, the stock is already in a strong uptrend and is trading **close to near-term resistance (~24.62)** after a volatile move (regular session -2.74%). With **heavy insider selling** and **no proprietary buy signals today**, the risk/reward for an immediate long-term entry is not favorable versus waiting for a better setup.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Technical Analysis
Trend is **bullish**: moving averages are stacked positively (**SMA_5 > SMA_20 > SMA_200**), indicating sustained upward momentum. MACD histogram is **positive (0.503)** but **contracting**, suggesting upside momentum is still present but weakening short-term. RSI(6) at **66.02** is near the upper end of neutral (not overbought, but getting stretched).
Key levels: current post-market price **23.83** sits below **R1 ~24.618** (near-term ceiling). Pivot support is around **21.371**; a break below that would weaken the near-term structure. Overall: technically strong longer-term trend, but **near resistance with fading momentum**, which is not an ideal immediate entry for an impatient long-term buyer.
Analyst Ratings and Price Target Trends
Recent analyst trend is **sharply positive** (clustered upgrades/price-target raises in mid-Dec 2025 after Phase 3 VITESSE data). Notable targets: **$40 (H.C. Wainwright), $45 (Citizens), $48 (Cantor Fitzgerald), $51 (Guggenheim)** with Buy/Overweight/Outperform ratings.
Wall Street pros: de-risked Phase 3 outcome, clearer path to **BLA in 1H 2026**, differentiated and potentially more convenient/safe approach vs existing oral immunotherapy.
Wall Street cons (implied by situation/data): still **loss-making**, execution/regulatory timeline ahead, and near-term sentiment mixed due to **heavy insider selling**.
Politicians / Congress: **No recent congress trading data available** (no notable politician activity provided).
Wall Street analysts forecast DBVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DBVT is 46.4 USD with a low forecast of 40 USD and a high forecast of 51 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast DBVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DBVT is 46.4 USD with a low forecast of 40 USD and a high forecast of 51 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 23.770
Current: 23.770
